Vaxcyte's 'stunning' 31-valent pneumococcal vaccine win against Pfizer's Prevnar 20 has analysts thinking big

Vaxcyte unveiled what analysts called “stunning” phase 1/2 data for its 31-valent pneumococcal vaccine candidate that, if replicated in a large pivotal study, could pose a serious threat to Pfizer’s stalwart Prevnar 20.